Like! I'll take .53...
INVESTMENT SUMMARY
Prescient has sharpened its focus on lead anti-cancer compound PTX-200 and plans to add a Phase Ib trial in acute myeloid leukaemia (AML) to the ongoing Phase I/II trials in breast and ovarian cancers. It has raised ~A$2m through a share purchase plan and placement, which will fund operations until 2017. We raise our valuation to A$49m (A$0.53/share), with the addition of the AML indication for PTX-200 more than offsetting the deferral of Phase 1b trials for PTX-100.
- Forums
- ASX - By Stock
- PTX
- Ann: Edison Investment Research Initiates Coverage
Ann: Edison Investment Research Initiates Coverage, page-2
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PTX (ASX) to my watchlist
|
|||||
Last
4.1¢ |
Change
-0.003(6.82%) |
Mkt cap ! $33.01M |
Open | High | Low | Value | Volume |
4.2¢ | 4.3¢ | 4.1¢ | $10.02K | 237.3K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 59843 | 4.1¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
4.2¢ | 3619 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 59843 | 0.041 |
9 | 226751 | 0.040 |
4 | 374358 | 0.039 |
3 | 750222 | 0.038 |
9 | 742682 | 0.037 |
Price($) | Vol. | No. |
---|---|---|
0.042 | 3619 | 1 |
0.043 | 172342 | 1 |
0.044 | 285807 | 3 |
0.045 | 423919 | 4 |
0.046 | 298002 | 2 |
Last trade - 13.50pm 10/07/2024 (20 minute delay) ? |
Featured News
PTX (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO
Charles Armstrong
CEO
SPONSORED BY The Market Online